With experience over 35 years in leadership roles at companies across the biotech and pharmaceutical sector, Legault will be a key part of the team as Egle deploys its technology platforms to construct a drug pipeline of novel immunotherapies targeting suppressor regulatory T cells (Tregs).
Over the past five years, Legault has been at the cutting-edge of innovative oncology therapeutics, serving as director of Syndax Pharmaceuticals, and chairman of the board at Artios Pharma, Bicycle Therapeutics, and Sitryx Therapeutics.
This first-hand experience of wide-ranging novel approaches to treat cancer and autoimmune conditions places Legault in a very strong position as he joins the team at Egle Therapeutics.
In his early career, Legault held global roles including president, CEO and CFO at legacy companies of the Sanofi-Aventis group.
Over the past decades, Legault has continued to build a rich profile of experience, holding C-suite executive roles and serving as a board member at over 20 pharmaceutical and biotechnology companies such as Prosidion Ltd., NPS, Armo, Clementia, Poxel, Amolyt Pharma, Urovant Sciences and others.
Established in early 2020 as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur, and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research director, Head of the Translational Immunotherapy Team TransImm at Institut Curie), Egle Therapeutics develops First-In-Class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
The key element of Egle's core approach is the leveraging of its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories